COMPANY

Aavogen Inc.

HQ: Rockville, MD source · aavogen.com ↗ · Mid-Atlantic

Aavogen is developing gene therapeutics for muscle wasting diseases like inclusion body myositis, Duchenne muscular dystrophy and heart failure. From company website Source · Oct 12, 2026

Keywords: gene therapy

Location: Rockville, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

9NIH grants

Timeline

Sep 5, 2025 Grant Government grant — SBIR: $350,000 (annual award, as published), announced Sep 5, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Funding

Last 2 years.

Sep 5, 2025 Government grant — SBIR: $350,000 (annual award, as published), announced Sep 5, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

NIH awards 9

Annual award amounts. Total $4.4M.

Jul 12, 2024 NIH award 5R43AR083297-02 FY2024: $134,000 awarded for that fiscal year; activity R43 (SBIR); PI RODGERS, BUEL DANTESE; recipient as written: AAVOGEN, INC., ROCKVILLE, MD. Development of optimized adeno-associated vi source ↗
Aug 16, 2023 NIH award 5R44AG079825-02 FY2023: $973,558 awarded for that fiscal year; activity R44 (SBIR); PI RODGERS, BUEL DANTESE; recipient as written: AAVOGEN, INC., ROCKVILLE, MD. Preclinical Development of a Novel Gene Ther source ↗
Aug 2, 2023 NIH award 1R43AR083297-01 FY2023: $140,152 awarded for that fiscal year; activity R43 (SBIR); PI RODGERS, BUEL DANTESE; recipient as written: AAVOGEN, INC., ROCKVILLE, MD. Development of optimized adeno-associated vi source ↗
Sep 23, 2022 NIH award 1R44AG079825-01A1 FY2022: $904,058 awarded for that fiscal year; activity R44 (SBIR); PI RODGERS, BUEL DANTESE; recipient as written: AAVOGEN, INC., ROCKVILLE, MD. Preclinical Development of a Novel Gene Th source ↗
Feb 26, 2021 NIH award 5R44CA221539-04 FY2021: $134,809 awarded for that fiscal year; activity R44 (SBIR); PI RODGERS, BUEL DANTESE; recipient as written: AAVOGEN, INC., ROCKVILLE, MD. AVGN7, a Novel Gene Therapeutic for Treating source ↗
Sep 5, 2019 NIH award 5R44CA221539-03 FY2019: supplement or administrative line (under $1,000); activity R44 (SBIR); PI RODGERS, BUEL DANTESE; recipient as written: AAVOGEN, INC., ROCKVILLE, MD. AVGN7, a Novel Gene Therapeutic for Treating Cance source ↗
Aug 19, 2019 NIH award 1R43AR075438-01 FY2019: $224,999 awarded for that fiscal year; activity R43 (SBIR); PI RODGERS, BUEL DANTESE; recipient as written: AAVOGEN, INC., ROCKVILLE, MD. Preclinical Validation of AVGN7 for Treating source ↗
Aug 31, 2018 NIH award 5R44CA221539-02 FY2018: $660,235 awarded for that fiscal year; activity R44 (SBIR); PI RODGERS, BUEL DANTESE; recipient as written: AAVOGEN, INC., ROCKVILLE, MD. AVGN7, a Novel Gene Therapeutic for Treating source ↗
Sep 25, 2017 NIH award 1R44CA221539-01 FY2017: $1,206,955 awarded for that fiscal year; activity R44 (SBIR); PI RODGERS, BUEL DANTESE; recipient as written: AAVOGEN, INC., ROCKVILLE, MD. AVGN7, a Novel Gene Therapeutic for Treati source ↗